Full Press Release Details
Presents NASH Interim Results at BioShares Conference
Australia, 7 August 2017: Australian biopharmaceutical company, Immuron Limited (ASX:IMC; NASDAQ:IMRN), is please to provide
investors with a copy of its recent presentation slide deck showcased at the 2017 BioShares Biotech Summit conference held in
Queenstown, New Zealand.
Dr Jerry Kanellos, presented clinical data from the Company's recent interim analysis report from the IMM-124E Phase II
study in NASH during the Fibrosis session entitled "Insights to Fibrosis Drug Discovery and Development".
copy of the presentation slide deck is appended to this announcement.
| COMPANY CONTACT: | US INVESTORS RELATIONS: |
| Jerry Kanellos | Jon Cunningham |
| Chief Executive Officer | RedChip Companies, Inc. |
| AUS Ph: + 61 (0)3 9824 5254 | US Ph: +1 (407) 644 4256, (ext. 107) |
| jerrykanellos@immuron.com | jon@redchip.com |
| AUSTRALIA INVESTORS RELATIONS: | US PUBLIC RELATIONS: |
| Peter Taylor | Eric Fischgrund |
| NWR Communications | FischTank - Marketing and PR |
| AUS ph: Ph: +61 (0)4 1203 6231 | US Ph: +1 (646) 699 1148 |
| peter@nwrcommunications.com.au | eric@fischtankpr.com |
Limited (NASDAQ: IMRN; ASX: IMC), is a biopharmaceutical company focused on developing and commercialising oral immunotherapeutics
for the treatment of gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development
therapeutic cycle. The Company currently markets and sells Travelan for the prevention of Travellers' Diarrhea and
its lead clinical candidate, IMM-124E, is in Phase 2 clinical trials for NASH, ASH and Pediatric NAFLD. Immuron's second
clinical stage asset, IMM-529, is targeting C. difficile Infections (CDI). These products together with the Company's
other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large
unmet need in the global immunotherapy market.
more information visit: http://www.immuron.com
press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to,
any statements relating to our growth strategy and product development programs and any other statements that are not historical
facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties
that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual
results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain,
perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and
development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical
and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the
early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual
property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking
to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations
or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.